SightfileU.S. market data from official filings

Companies › BRTX

Biorestorative Therapies Inc (BRTX)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001505497 · EDGAR filings · Updated 2026-07-24

Biorestorative Therapies Inc (BRTX) has reported institutional ownership of 2.7%, with 11 institutional managers holding positions valued at $184.2K per the latest 13F reporting period. SEC filings include an active bankruptcy or receivership filing (8-K Item 1.03), non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Institutional ownership
2.7%
Institutional managers
11
Reported 13F value
$184.2K
Insider activity
2 trans.
$0 net flat
Data flags
5 active
from SEC filings

Filings this week (1)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Biorestorative Therapies Inc has 11 institutional holders and institutional ownership of 2.7%.

Insider activity

Insiders reported 2 transactions (0 buys, 0 sells) across 2 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-14 (recurring since 2021-03-18) — source filing. The authoritative details are those stated in the filing itself.
Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2024-05-24 (recurring since 2024-05-24) — source filing. The authoritative details are those stated in the filing itself.
Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2024-05-24 (recurring since 2024-05-24) — source filing. The authoritative details are those stated in the filing itself.
Active bankruptcy or receivership filing (8-K Item 1.03), most recently filed 2020-11-20 (recurring since 2020-03-20) — source filing. The authoritative details are those stated in the filing itself.
Active triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04), most recently filed 2020-03-20 (recurring since 2020-02-11) — source filing. The authoritative details are those stated in the filing itself.

Related companies

VIRAX BIOLABS GROUP LTD (VRAX) · IO BIOTECH INC (IOBTQ) · VYOME HOLDINGS INC (HIND) · ENvue Medical Inc (FEED) · MATINAS BIOPHARMA HLDGS INC (MTNB) · XTL BIOPHARMACEUTICALS LTD (XTLB)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-24.